CD3E and cancer: CD38 bispecific T-cell-engaging (BiTE) antibodies belong to a new class of immunotherapeutic agents, which can mediate dual specific binding to the CD38 and the CD3e chain on T cells, thereby activating T cells and recruiting them in proximity of target cancer cells to efficiently induce T-cell-mediated cytotoxicity.